Anti-BRCA1 antibody (ab238983)
Key features and details
- Rabbit polyclonal to BRCA1
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-BRCA1 antibody
See all BRCA1 primary antibodies -
Description
Rabbit polyclonal to BRCA1 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human
Predicted to work with: Chimpanzee, Rhesus monkey, Gorilla, Orangutan -
Immunogen
Synthetic peptide corresponding to Human BRCA1 aa 979-993.
Database link: P38398 -
Positive control
- WB: MCF7, HeLa, PC3 and NIH/3T3 cell extracts; Mouse lung extract. IHC-P: Human breast cancer tissue; Mouse liver, testis, spinal cord, brain and pancreas tissue; Rat testis, ovary, pancreas and brain tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol -
Concentration information loading...
-
Purity
Affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab238983 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/50 - 1/200.
|
|
WB |
1/500 - 1/2000. Predicted molecular weight: 207 kDa.
|
Notes |
---|
IHC-P
1/50 - 1/200. |
WB
1/500 - 1/2000. Predicted molecular weight: 207 kDa. |
Target
-
Function
E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. -
Tissue specificity
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines. -
Pathway
Protein modification; protein ubiquitination. -
Involvement in disease
Defects in BRCA1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.
Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.
Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705]. -
Sequence similarities
Contains 2 BRCT domains.
Contains 1 RING-type zinc finger. -
Domain
The BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites.
The RING-type zinc finger domain interacts with BAP1. -
Post-translational
modificationsPhosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation. -
Cellular localization
Cytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex. - Information by UniProt
-
Database links
- Entrez Gene: 672 Human
- Entrez Gene: 12189 Mouse
- Entrez Gene: 497672 Rat
- Entrez Gene: 712634 Rhesus monkey
- Omim: 113705 Human
- SwissProt: Q9GKK8 Chimpanzee
- SwissProt: Q6J6I8 Gorilla
- SwissProt: P38398 Human
see all -
Alternative names
- BRCA 1 antibody
- BRCA1 antibody
- BRCA1 DNA repair associated antibody
see all
Images
-
All lanes : Anti-BRCA1 antibody (ab238983) at 1/500 dilution
Lane 1 : Wild-type MCF7 cell lysate
Lane 2 : BRCA1 heterozygous knockout MCF7 cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : PC-3 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 207 kDa
Observed band size: 270 kDa why is the actual band size different from the predicted?Western blot: Anti-BRCA1 antibody (ab238983) staining at 1/500 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab238983 was shown to bind specifically to BRCA1. A band was observed at 270 kDa in wild-type MCF7 cell lysates with a reduction in signal observed in the BRCA1 heterozygous knockout cell line ab286284 (heterozygous knockout cell lysate ab300209). To generate this image, wild-type and BRCA1 heterozygous knockout MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
-
All lanes : Anti-BRCA1 antibody (ab238983) at 1/1000 dilution
Lane 1 : MCF7 (human breast adenocarcinoma cell line) cell extract
Lane 2 : HeLa (human epithelial cell line from cervix adenocarcinoma) cell extract
Lane 3 : NIH/3T3 (mouse embryo fibroblast cell line) cell extract
Lane 4 : Mouse lung tissue extract
Lysates/proteins at 25 µg per lane.
Secondary
All lanes : HRP Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution
Developed using the ECL technique.
Predicted band size: 207 kDaBlocking and dilution buffer: 3% nonfat dry milk in TBST.
Exposure time: 1 second.
-
Paraffin-embedded human breast cancer tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded rat testis tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded rat ovary tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded rat brain tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded rat pancreas tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded mouse liver tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded mouse testis tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded mouse spinal cord tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded mouse brain tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
-
Paraffin-embedded mouse pancreas tissue stained for BRCA1 using ab238983 at 1/100 dilution in immunohistochemical analysis.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab238983 has been referenced in 5 publications.
- Wang Q et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun 13:3022 (2022). PubMed: 35641483
- Liu X et al. BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway. PeerJ 10:e14052 (2022). PubMed: 36193432
- Xu H et al. YTHDF2 alleviates cardiac hypertrophy via regulating Myh7 mRNA decoy. Cell Biosci 11:132 (2021). PubMed: 34266473
- Zheng J et al. Paeonol Pretreatment Attenuates Anoxia-Reoxygenation Induced Injury in Cardiac Myocytes via a BRCA1 Dependent Pathway. Chem Pharm Bull (Tokyo) 68:1163-1169 (2020). PubMed: 33268648
- Sun HB et al. The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. Oncol Lett 18:6385-6396 (2019). PubMed: 31807162